Skip to main content
SpringerLink
Log in

Chemotherapy of Nontuberculous Mycobacterial Diseases

  • Chapter
Mycobacteria

Part of the book series: Chapman & Hall Medical Microbiology Series ((CHMMS))

Abstract

Nontuberculous mycobacteria can be found throughout the environment and readily gain access to clinical specimens. The significance of an isolate can, therefore, be doubtful and it is necessary to establish criteria which determine significance and which indicate whether or not treatment is required. The most important considerations are the type of specimen from which the organism is isolated, the number of isolates, the degree of growth, and the identity of the organism. Predisposing factors on the part of the patient and the clinical presentation can also help to determine the significance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Campbell IA and Jenkins PA (1995) Opportunist mycobacterial infections. In: Brewis RAL, Corrin B, Geddes DM, Gibson GJ, eds. Respiratory Medicine. London: WB Saunders.

    Google Scholar 

  2. Wallace RJ Jr, Swenson JM, Silcox VA, Good RC, Tischen JA, Stone MS (1983) Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 5:657.

    Article  PubMed  Google Scholar 

  3. Griffith DE, Girard WM, Wallace RJ, Jr (1993) Clinical features of pulmonary disease caused by rapidly growing mycobacteria. Am Rev Respir Dis 147:1271.

    PubMed  CAS  Google Scholar 

  4. Schaefer WB, Wolinsky E, Jenkins PA, Marks J (1973) Mycobacterium szulgai, a new pathogen. Am Rev Respir Dis 108:1320.

    PubMed  CAS  Google Scholar 

  5. Rose HD, Dorff GJ, Louwasser M, Sheth NK (1982) Pulmonary and disseminated Mycobacterium simiae infection in humans. Am Rev Respir Dis 126:1110.

    PubMed  CAS  Google Scholar 

  6. Clague H, Hopkins CA, Roberts C, Jenkins PA (1985) Pulmonary infection with Mycobacterium gordonae in the presence of bronchial carcinoma. Tubercle 66:61.

    Article  PubMed  CAS  Google Scholar 

  7. Tsukamura M, Kia N, Otsuka W, Shimoide H (1983) A study of the taxonomy of the Mycobacterium nonchromogenicum complex and report of six cases of lung infection due to Mycobacterium nonchromogenicum. Microbiol Immunol 27:219.

    PubMed  CAS  Google Scholar 

  8. Marks J (1961) The design of sensitivity tests on tubercle bacilli. Tubercle 42:314.

    Article  PubMed  CAS  Google Scholar 

  9. Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP (1983) Pulmonary infection with Mycobacterium kansasii in Wales, 1970–9: review of treatment and response. Thorax 38:271.

    Article  PubMed  CAS  Google Scholar 

  10. Wallace RJ Jr., Dunbar D, Brown BA, Onyi G, Dunlap R, Ahn CH, Murphy DT (1994) Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 18:736.

    Article  PubMed  CAS  Google Scholar 

  11. Heifits L, Mor N, van der Kolk J (1993) Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 37:2364.

    Article  Google Scholar 

  12. Meier A, Heifets L, Wallace RJ Jr., Zhang Y, Brown BA, Sander P, Böttger EC (1996) Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 174:354.

    Article  PubMed  CAS  Google Scholar 

  13. Meier A, Kirschner P, Springer B, Steingrube VA, Brown BA, Wallace RJ Jr, Böttger EC (1994) Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 38:381.

    Article  PubMed  CAS  Google Scholar 

  14. Wallace RJ Jr, Meier A, Brown BA, Zhang Y, Sander P. Onyi GO, Böttger EC (1996) Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 40:1676.

    PubMed  CAS  Google Scholar 

  15. Hunter AM, Campbell IA, Jenkins PA (1981) Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex. Thorax 36:326.

    Article  PubMed  CAS  Google Scholar 

  16. Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP (1984) Pulmonary infection with Mycobacterium xenopi: review of treatment and response. Thorax 39:376.

    Article  PubMed  CAS  Google Scholar 

  17. Banks J, Jenkins PA, Smith AP (1985) Pulmonary infection with Mycobacterium malmoense—a review of treatment and response. Tubercle 66:197.

    Article  PubMed  CAS  Google Scholar 

  18. Sison JP, Yao Y, Kemper CR, et al. (1996) Treatment of Mycobacterium avium complex infection: Do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J Infect Dis 173:677.

    Article  PubMed  CAS  Google Scholar 

  19. Banks J, Jenkins PA (1987) The effect of combined versus single antituberculosis drugs on in vitro sensitivities patterns of non-tuberculous mycobacteria. Thorax 42:838.

    Article  PubMed  CAS  Google Scholar 

  20. Christensen EE, Dietz GW, Ahn CH, Chapman JS, Murry RC, Anderson J, Hurst GA (1981) Initial roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M. kansasii, and M. intracellulare infections. Chest 80:132.

    Article  PubMed  CAS  Google Scholar 

  21. Swensen SJ, Hartman TE, Williams DE (1994) Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 105:49.

    Article  PubMed  CAS  Google Scholar 

  22. BTS Research Committee (1994) Mycobacterium kansasii pulmonary infection: a prospective study of the results of 9 months of treatment with rifampicin and ethambutol. Thorax 49:442.

    Article  Google Scholar 

  23. Wallace RJ Jr, O’Brien R, Glassroth J, Raleigh J, Dutt A (1990) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. NTM Statement, American Thoracic Society.

    Google Scholar 

  24. Yeager H Jr, Raleigh JW (1973) Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis 108:547.

    PubMed  Google Scholar 

  25. Ahn CH, Ahn SS, Anderson RA, Murphy DT, Mammo A (1986) A four drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 134:438.

    PubMed  CAS  Google Scholar 

  26. Dutt AK, Stead WW (1979) Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med 67:449.

    Article  PubMed  CAS  Google Scholar 

  27. Etzkorn ET, Aldarondo S, McAllister CK, Matthews J, Ognibene AJ (1986) Medical therapy of Mycobacterium avium-intracellulare pulmonary disease. Am Rev Respir Dis 134:442.

    PubMed  CAS  Google Scholar 

  28. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH (1994) Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 149:1335.

    PubMed  Google Scholar 

  29. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr (1996) Azithromycin activity against Mycobacterium avium complex lung disease in HIV negative patients. Clin Infect Dis 23:983.

    Article  PubMed  CAS  Google Scholar 

  30. Havlir DV, Dubé MP, Sattler FR, et al. (1996) Prophylaxis against disseminated Mycobacterium avium complex with weekly azith ro mycin, daily rifabutin, or both. N Engl J Med 335:392.

    Article  PubMed  CAS  Google Scholar 

  31. Dautzenberg B, Piperno D, Diot P, Truffot -Pernot C, Chauvin J-P, and the Clarithromycin Study Group of France (1995) Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 107:1035.

    Article  PubMed  CAS  Google Scholar 

  32. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT (1996) Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 153:1766.

    PubMed  Google Scholar 

  33. Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, Eron LJ, Sparti PD, Bihari B, Kaufman DL, Stern JJ, Pearce DD, Weinberg WG, La Marca A, Siegal FP (1993) Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 329:828.

    Article  PubMed  CAS  Google Scholar 

  34. Dautzenberg B, Castellani P, Pellegrin J-L, Vittecoq D, Truffot-Pernot C, Pirotta N, Sassella D (1996) Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Antimicrob Agents Chemother 40:1722.

    PubMed  CAS  Google Scholar 

  35. Sullam PM, Gordin FM, Wynne BA, and the Rifabutin Treatment Group (1994) Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex infection. Clin Infect Dis 19:84.

    Article  Google Scholar 

  36. Shafrin SD, Singer J, Zarowny DP, et al. (1996) A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol and clarithromycin versus rifampin, ethambutol, clofazimine and ciprofloxacin. N Engl J Med 335:377.

    Article  Google Scholar 

  37. Dautzenberg, B (1996) Rifabutin in the treatment of Mycobacterium avium complex infection: Experience in Europe. Clin Infect Dis 22(Suppl 1):533.

    Article  Google Scholar 

  38. France AJ, McLeod DT, Calder MA, Seaton A (1987) Mycobacterium malmoense infections in Scotland: an increasing problem. Thorax 42:593.

    Article  PubMed  CAS  Google Scholar 

  39. Hoffner SE, Hjelm U, Källenius (1993) Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. Antimicrob Agents Chemother 37:1285.

    Article  PubMed  CAS  Google Scholar 

  40. Costrini AM, Mahler DA, Gross WM, et al. (1981) Clinical and roentographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis 123:104.

    PubMed  CAS  Google Scholar 

  41. Smith MJ, Citron KM (1983) Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax 38:373.

    Article  PubMed  CAS  Google Scholar 

  42. Dautzenberg B, Papillon F, Lepitre M, Truffot-Pernod CH, Chauvin JP (1993) Mycobacterium xenopi infections treated with clarithromycin-containing regimens. Abstract no. 1125 Thirty-third Interscience Conference of Antimicrob Agents and Chemother, New Orleans, LA, USA.

    Google Scholar 

  43. O’Brien RJ, Geiter LJ, Snider DE Jr (1987) The epidemiology of non-tuberculous mycobacterial diseases in the United States. Am Rev Respir Dis 135:1007.

    PubMed  Google Scholar 

  44. Kennedy TP, Weber DJ (1994) Non-tuberculous mycobacteria: an underappreciated cause of geriatric lung disease. Am J Respir Crit Care Med 149:1654.

    PubMed  CAS  Google Scholar 

  45. Brown BA, Wallace RJ Jr, Onyi GO, DeRosas V, Wallace RJ III (1992) Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae and M. chelonae-like organisms. Antimicrob Agents Chemother 36:180.

    Article  PubMed  CAS  Google Scholar 

  46. Wallace RJ Jr, Bedsole G, Sumter G, Sanders CV, Steel LC, Brown BA, Smith J, Graham DR (1990) Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 34:65.

    Article  PubMed  CAS  Google Scholar 

  47. Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C (1985) Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 28:807.

    Article  PubMed  CAS  Google Scholar 

  48. Wallace RJ Jr., Brown BA, Onyi GO (1991) Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 35:773.

    Article  PubMed  CAS  Google Scholar 

  49. Yew WW, Kwan SYL, Wong PC, Lee J (1990) Ofloxacin and imipenem in the treatment of Mycobacterium fortuitum and Mycobacterium chelonae lung infections. Tubercle 71:131.

    Article  PubMed  CAS  Google Scholar 

  50. Burns DN, Rohatgi PK, Rosenthal R, Seiler M, Gordin FM (1990) Disseminated Mycobacterium fortuitum successfully treated with combination therapy including ciprofloxacin. Am Rev Respir Dis 142:468.

    PubMed  CAS  Google Scholar 

  51. Pacht ER (1990) Mycobacterium fortuitum lung abscess: resolution with prolonged trimethoprim/sulfamethoxazole therapy. Am Rev Respir Dis 141:1599.

    PubMed  CAS  Google Scholar 

  52. Ichiyama S, Tsukamura M (1987) Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum. Chest 92:1110.

    Article  PubMed  CAS  Google Scholar 

  53. Brown BA, Wallace RJ Jr, Onyi GO (1992) Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 36:1987–1990.

    Article  PubMed  CAS  Google Scholar 

  54. Hawkins CC, Gold JWM, Whimbey E, Kiehn TE, Brannon P, Cammarata R, Brown AE, Armstrong D (1986) Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 105:184.

    PubMed  CAS  Google Scholar 

  55. Dautzenberg B, Truffot C, Legris S, et al. (1991) Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 144:564.

    Article  PubMed  CAS  Google Scholar 

  56. Chaisson RE, Benson CA, Dube MP, et al. and the Aids Clinical Trial Group Protocol 157 Study Team (1994) Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose ranging study in patients with AIDS. Ann Intern Med 121:905.

    PubMed  CAS  Google Scholar 

  57. Young LS, Wiviott L, Wu M, Kolonski P, Bolan R, Inderlied CB (1991) Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 338:1107.

    Article  PubMed  CAS  Google Scholar 

  58. Kemper CA, Havlir D, Haghighat D, et al. (1994) The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 170:157.

    Article  PubMed  CAS  Google Scholar 

  59. Pierce M, Crampton S, Henry D, et al. (1996) A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 335:384.

    Article  PubMed  CAS  Google Scholar 

  60. Haviir DV, Dubé MP, Sattler FR, et al. and the California Collaborative Treatment Group (1996) Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 335:392.

    Article  Google Scholar 

  61. Stanford JL. Newer tuberculins, their reactivity profile and impact on treatment in developing countries. Indian Paediatrics (1991). Ed. V. Seth.

    Google Scholar 

  62. Jadavji T, Wong A (1996) Atypical mycobacteria cervical adenitis in normal children—Is clarithromycin effective? In: Program and Abstracts of The Third International Conference on the Macrolides Azalides and Streptogramins, Lisbon, Portugal, January 24–26, Abstract 7.23, p. 67.

    Google Scholar 

  63. Berger CH, Pfyffer GE, Nadal D (1996) Drug therapy of lymphadenitis with nontuberculous mycobacteria (NTM). In: Program and Abstracts of The Third International Conference on the Macrolides Azalides and Streptogramins, Lisbon, Portugal, January 24–26, Abstract 7.22, p. 67.

    Google Scholar 

  64. Green PA, von Reyn CF, Smith RP, Jr (1993) Mycobacterium avium complex parotid lymphadenitis: Successful therapy with clarithromycin and ethambutol. Ped Infect Dis J 12:615–616.

    Article  CAS  Google Scholar 

  65. White MP, Bangash H, Goel KM, Jenkins PA (1986) Non-tuberculous mycobacterial lymphadenitis. Arch Dis Child 61:368.

    Article  PubMed  CAS  Google Scholar 

  66. Wallace RJ Jr, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS (1983) Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 5:657.

    Article  PubMed  Google Scholar 

  67. Wallace RJ Jr, Musser JM, Hull SI, Silcox VA, Steele LC, Forrester GD, Labidi A, Selander SK (1989) Diversity and sources of rapidly growing mycobacteria associated with infections following cardiac surgery. J Infect Dis 159:708.

    Article  PubMed  Google Scholar 

  68. Wallace RJ Jr, Brown BA, Onyi GO (1992) Skin soft tissue, and bone infections due to Mycobacterium chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 166:405.

    Article  PubMed  Google Scholar 

  69. Wallace RJ Jr., Tanner D, Brennan PJ, Brown BA (1993) Clinical trials of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 119:482.

    PubMed  Google Scholar 

  70. Mushat DM, Witzig RS (1995) Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin. Clin Infect Dis 20:1441.

    Article  Google Scholar 

  71. Maxson S, Schutze GE, Jacobs RF (1994) Mycobacterium abscessus osteomyelitis: treatment with clarithromycin. Infect Dis Clin Prac 3:203.

    Article  Google Scholar 

  72. Cynamon MH, Palmer GS (1982) In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins. Antimicrob Agents Chemother 22:1079.

    Article  PubMed  CAS  Google Scholar 

  73. Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG (1985) Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 152:500.

    Article  PubMed  Google Scholar 

  74. Yew WW, Kwan SYL, Ma WK, Mok CK (1989) Combination of ofloxacin and amikacin in the treatment of sternotomy wound infection. Chest 95:1051.

    Article  PubMed  CAS  Google Scholar 

  75. Pang Y, Brown BA, Steingrube VA, Wallace RJ Jr., Roberts MC (1994) Tetracycline resistance determinants in Mycobacterium and Streptomyces species. Antimicrob Agents Chemother 38:1408.

    Article  PubMed  CAS  Google Scholar 

  76. Wallace RJ Jr., Hull SI, Bobey DG, Price KE, Swenson JM, Steele LC, Christenson L (1985) Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Am Rev Respir Dis 132:409.

    PubMed  CAS  Google Scholar 

  77. Franklin DJ, Starke JR, Brady MT, Brown BA, Wallace RJ Jr (1994) Chronic otitis media after tympanotomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Am J Otol 15:313.

    PubMed  CAS  Google Scholar 

  78. Dalovisio JR, Pankey GA, Wallace RJ Jr, Jones DB (1981) Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis 3:1068.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. I. A. Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. A. Jenkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard J. Wallace Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chicago College of Medicine, University of Illinois, Chicago, Illinois, USA

    Pattisapu R. J. Gangadharam Ph.D. (Professor of Medicine, Microbiology, and Pathology, Director of Mycobacteriology Research) (Professor of Medicine, Microbiology, and Pathology, Director of Mycobacteriology Research)

  2. Public Health Laboratory Service, University Hospital of Wales, UK

    P. Anthony Jenkins Ph.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Campbell, I.A., Jenkins, P.A., Wallace, R.J. (1998). Chemotherapy of Nontuberculous Mycobacterial Diseases. In: Gangadharam, P.R.J., Jenkins, P.A. (eds) Mycobacteria. Chapman & Hall Medical Microbiology Series. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-7511-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-7511-5_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4615-7513-9

  • Online ISBN: 978-1-4615-7511-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation